April 2010

NovaPACS client base expands in Louisiana ()
CCI: Mortality higher in CAD patients who undergo partial revascularization ()
NEJM: Valsartan, not nateglinide better reduced diabetes in NAVIGATOR ()
NCHS: 45% of adult Americans suffer from cardiac-related diseases ()
Medtronic seeks to buy ATS Medical for $370M ()
Feature: Remote monitoring programs improve outcomes, save money ()
Spectranetics Q1 net loss narrows on higher revenues ()
FDA expands external defib recall to 280K devices ()
Atherotech offers lifestyle education for heart patients ()
Court approves St. Jude's settlement over pacemaker patent ()
Commentary: My life as a female with a pacemaker ()
Forest drops out of $340M diabetes drug deal with Phenomix ()
Physio-Control launches STEMI management system upgrades ()
J&J's diabetes unit bolsters its Q1 ()
NICE releases guidlines to better manage unstable angina and NSTEMI ()
Radiology: Tumor detection on chest x-ray is observer dependent ()
ATS: California sees better outcomes after increasing CABG transparency ()
Edwards enrolls patients into trial to evaluate trancatheter heart valve ()
ASNC: Pharmacologic stress update: Adenosine A2a agonists ()
Feature: UNC to investigate necessity of Plavix black box warning ()
AIM: Rosuvastatin decreases CVD events in patients 70+ ()
ACP: EHRs critical to effective reporting of quality measures ()
Study: Diabetics at 40% greater risk for a-fib ()
Medtronic completes $500M purchase of Invatec ()
Survey: Healthcare execs pessimistic about healthcare reform bill ()
Spacelabs releases two ECG devices ()
FDA issues Class I recall for Physio's Lifepak devices ()
Lancet: Liraglutide better than sitagliptin for certain diabetes patients ()
Siemens launches 'cockpit' technologies for interventional suites ()
Bayer taps Novartis exec as new CEO, board chair ()
AIM: U.S. News & World Report's hospital rankings are too subjective ()
Circulation: Lack of medical adherence after PCI increases death ()
California Medical Assn. withdraws from state physician-rating program ()
NovaRad releases single-user RIS/PACS ()
IMS: Pharma market to reach $1.1 trillion by 2014, generics climbing ()
Vascular Solutions reports revenue, income jump in Q1 ()
Cardiovascular Systems lands $29M debt facility ()
Edwards' Q1 income slips due to increased spending ()
Survey: Hospitals need more work on quality measures, cost containment ()
Moody's: Pharma debt rises 177%, patent expiries could negate cash flow ()
JACC: For CTO recanalization, DES trumps BMS ()
Managing A-Fib: Expanding the Armamentarium of Therapies ()
The ACC Corner: Professionalism, Patient Partnerships Key to Real Reform ()
Are Patient Portals Loss Leaders for Practices? ()
CTO Treatment Advances: Physician Education Needed to Spread the Word ()
University of Colorado Hospital Puts Patient Hearts into Physicians Hands ()
Implantable Device Success: Volume Matters ()
First Word: A-Fib, ICDs and the Internet ()
The Back Page: Web-based Claims Clearinghouse Eases Billing & Coding Challenges ()
HealthAffairs: Physician-owned surgicenters lead to higher volume, profits ()
Study: Taped consultations help patients better understand CABG ()
Lancet: For children with cardiac arrest, conventional CPR is best ()
Endologix enrolls patients in percutaneous aortic aneurysm repair trial ()
Baxter nabs Hantson for prez ()
Feature: Cleveland Clinic leads kick off for start-up incubator ()
AJC: For left main disease, PCI with DES is safe alternative to CABG ()
Circulation: Malpractice fears compel cardiologists to order unnecessary tests ()
NEJM: Jury remains out on antiplatelet therapy after one year post-DES ()
Survey: Hospital/practice integration has challenges, rewards ()
AIM: Are hospitals risking death for elderly by implanting ICDs? ()
Vital to develop pediatric cardiac app with Arkansas Children's Hospital ()
Circulation: Socioeconomics trump age, sex for post-CABG mortality ()
ev3 to supply drug-eluting catheter for Medrad trial ()
CPR quality better at scene, rather than in transport ()
In developed countries, most CKD patients die of cardiovascular causes ()
Sanofi inks $335M diabetes deal ()
Feature: Midwest cardiac arrest care model may save lives, money ()
AHA: Temp-dependent drug may prevent blood clots during hypothermia ()
Circulation: Transcatheter valve-in-valve implants are 98% effective ()
Cordis begins enrollment in stent graft system trial ()
Bancroft becomes permanent CFO at Bristol-Myers ()
Two Atlanta hospitals discuss a partnership ()
NovaRad scores sunshine state installs ()
DoJ steps in to help fight battle against Georgia heart center ()
First-ever European guidelines issued on preventing diabetes ()
Radiology: VC finds cancers outside colon in asymptomatic patients ()
Case Study: Columbia discovers fiscal benefits with clinical trial oversight ()
Study: VC elucidates prevalence of urinary stone disease in asymptomatic patients ()
Pharma paid Vermont providers $2.6M in FY09drop from prior year ()
AstraZeneca vindicated in Seroquel court decision ()
ACC: Female STEMI patients have longer D2B times, comparable mortality rates ()
FDA warns Edwards for not reporting heart valve concerns ()
ACC: ProVation touts trend of ASCs adopting cardiology-specific EHRs ()
JAMA: Docs question how expanded statin indications should affect practice ()
JACC: Benefits of Multaq questioned ()
IMS: U.S. pharma sales reach $300B, generic drug sales swell in 2009 ()
Juventas begins enrollment of heart failure drug study ()
TeraRecon updates Aquarius iNtuition with iPad support ()
Report: Physician disciplinary action rates drop off in last decade ()
NICE revises lipid guidelines, revokes emphasis on Framingham Risk ()
Cubist stops R&D on cardiac surgery drug ()
HeartRhythm: A-fib increases dementia risk, including Alzheimer's ()
Medtronic to appeal heart valve patent loss, $74M reward to Edwards ()
ACC: MRIs can determine when to implant high-risk patients with ICDs ()
Feature: Meaningful use leaves medical images out in the cold ()
Lancet: Model shows optimal diabetes screening age, frequency ()
VIA Pharmaceuticals reduces workforce by 63% ()
ACC: Medrad focuses on thrombosis with new products, JETSTENT study ()
ACC: Comparing between hospital 30-day mortality rates "wrongheaded" ()